Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva UK has launched new Latanoprost 0.005% w/v eye drops solution 2.5ml, indicated for the treatment of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.
Subscribe to our email newsletter
Currently, Latanoprost is available as Xalatan (Latanoprost) from Pfizer, and is now introduced by Teva to fulfil generic prescriptions.
Teva commercial director Kim Innes said this is the company’s inaugural product launch for 2012 and their first day-one patent expiry of the year.
"It’s good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down,” Innes added.
Headquartered in Israel, Teva is committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.